Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A drug for preventing and treating fulminant hepatitis

An explosive, hepatitis technology, applied in the field of medicine, can solve the problems of difficult implementation, limited conservative treatment methods, and poor clinical prognosis

Active Publication Date: 2022-02-25
THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Once fulminant hepatitis develops, the condition will deteriorate rapidly. At present, supportive treatment is mainly aimed at various complications (hepatic encephalopathy, respiratory and circulatory failure, renal failure, coagulation disorders, infection, gastrointestinal bleeding). The disease progresses rapidly, conservative treatment options are limited, and the clinical prognosis is extremely poor
Liver transplantation is still the ultimate treatment for severe fulminant hepatitis, but it is very difficult to implement due to the limitation of transplantation conditions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A drug for preventing and treating fulminant hepatitis
  • A drug for preventing and treating fulminant hepatitis
  • A drug for preventing and treating fulminant hepatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0031] Male C57BL / 6 mice were purchased from the Animal Experiment Center of Chongqing Medical University, and raised in the SPF level breeding room of the Animal Experiment Center of Chongqing Medical University. Male C57BL / 6, age 6-8 weeks, body weight 18-21g, were divided into 4 groups, including normal control group, model group, normal administration group and treatment group.

[0032] The normal control group was given the same amount of PBS by the same injection method;

[0033] The model group was given intraperitoneal injection of LPS7.5μg / kg, D-GalN 500mg / kg;

[0034] The normal drug group was given intraperitoneal injection of 5 μg of C14-Tri-LAN-Gly per mouse;

[0035] The treatment group was given intraperitoneal injection of C14-Tri-LAN-Gly 5 μg / rat 6 hours before the administration of the model group (LPS / D-GalN).

[0036] Blood and liver tissue were collected 6 hours after LPS / D-GalN injection for subsequent analysis. Another two groups of mice were selected...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicine, in particular to a medicine for preventing and treating fulminant hepatitis. The research of the present invention shows that the NOD1 receptor agonist can significantly up-regulate the expression of A20 in the liver tissue. A20 (also known as TNFAIP3) is an anti-inflammatory signaling molecule. A20 can achieve anti-apoptotic effect by down-regulating the NF-κB signaling pathway, thereby protecting liver cells. Moreover, the NOD1 receptor agonist can also significantly reduce the serum ALT level and liver tissue cl-caspase3 level in mice with fulminant hepatitis, alleviate liver injury and hepatic cell apoptosis in mice with fulminant hepatitis. Therefore, NOD1 receptor agonists are considered to be useful in the treatment of fulminant liver injury.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a medicine for preventing and treating fulminant hepatitis. Background technique [0002] Fulminant hepatitis is currently considered to be the initiating link and common path of various serious liver diseases. Its onset is sudden and its prognosis is very poor. If it is not treated correctly, it can further lead to severe liver failure and multiple organ dysfunction, and it is very difficult to treat. Clinical mortality is high. Sepsis induced by LPS, a cell wall component of Gram-negative bacteria, plays a key role in fulminant hepatitis and is one of the common critical illnesses in ICU. When the intestinal permeability is increased due to various reasons, bacteria in the intestinal tract can enter the blood vessels of the intestinal wall and further reach the liver to cause an inflammatory response. [0003] LPS is a component of the outer wall of bacterial cells, and it i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/00A61P1/16
CPCA61K45/00A61P1/16
Inventor 殷文伟贾方任红
Owner THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com